Minimal residual disease in high-risk neuroblastoma shows a dynamic and disease burden-dependent correlation between bone marrow and peripheral blood

被引:10
作者
San Lin, Kyaw [1 ]
Uemura, Suguru [1 ]
Thwin, Khin Kyae Mon [1 ]
Nakatani, Naoko [1 ]
Ishida, Toshiaki [2 ]
Yamamoto, Nobuyuki [1 ]
Tamura, Akihiro [2 ]
Saito, Atsuro [2 ]
Mori, Takeshi [2 ]
Hasegawa, Daiichiro [2 ]
Kosaka, Yoshiyuki [2 ]
Nino, Nanako [1 ]
Nagano, China [1 ]
Takafuji, Satoru [1 ]
Iijima, Kazumoto [1 ]
Nishimura, Noriyuki [3 ]
机构
[1] Kobe Univ, Grad Sch Med, Dept Pediat, Kobe, Japan
[2] Kobe Childrens Hosp, Dept Hematol & Oncol, Kobe, Hyogo, Japan
[3] Kobe Univ, Grad Sch Hlth Sci, Dept Publ Hlth, Kobe, Hyogo, Japan
来源
TRANSLATIONAL ONCOLOGY | 2021年 / 14卷 / 08期
基金
日本学术振兴会;
关键词
Neuroblastoma (NB); Minimal Residual Disease (MRD); Peripheral Blood (PB); Circulating Tumor Cell (CTC); Bone Marrow (BM); Disseminated Tumor Cell (DTC); MOLECULAR-DETECTION; AORTIC ENDOTHELIUM; MESSENGER-RNAS; CELLS; CANCER; EXPRESSION; CHILDREN; PREDICTOR; DIAGNOSIS; SURVIVAL;
D O I
10.1016/j.tranon.2021.101019
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Neuroblastoma (NB) is the most common extracranial solid tumor in children and originates from sympathoa-drenal or Schwann cell precursors derived from neural crest. These neural crest derivatives also constitute the hematopoietic and mesenchymal stem cells in bone marrow (BM) that is the most frequent site of NB metas-tasis and relapse. In NB patients, NB cells have been pathologically detected in BM and peripheral blood (PB), and minimal residual disease (MRD) in BM and PB (BM-MRD and PB-MRD) can be monitored by quantitating several sets of NB-associated mRNAs (NB-mRNAs). Although previous studies have shown varying degrees of correlation between BM-MRD and PB-MRD, the underlying factors and/or mechanisms remains unknown. In the present study, we determined the levels of BM-MRD and PB-MRD by quantitating seven NB-mRNAs in 133 pairs of concurrently collected BM and PB samples from 19 high-risk NB patients with clinical disease evaluation, and examined their correlation in overall and subgroups of sample pairs. The levels of BM-MRD and PB-MRD were moderately ( r = 0.418, p < 0.001) correlated with each other in overall sample pairs. The correlation became strong ( r = 0.725, p < 0.001), weak ( r = 0.284, p = 0.008), and insignificant ( p = 0.194) in progression, stable, and remission subgroups of sample pairs, respectively. It also became stronger in subgroups of sample pairs with poor treatment responses and poor prognostic factors. Present study suggests that MRD in high-risk NB shows a dynamic and disease burden-dependent correlation between BM and PB.
引用
收藏
页数:7
相关论文
共 46 条
  • [31] Low burden of minimal residual disease prior to transplantation in children with very high risk acute lymphoblastic leukaemia: The NOPHO ALL2008 experience
    Ifversen, Marianne
    Turkiewicz, Dominik
    Marquart, Hanne V.
    Winiarski, Jacek
    Buechner, Jochen
    Mellgren, Karin
    Arvidson, Johan
    Rascon, Jelena
    Korgvee, Lenne-Triin
    Madsen, Hans O.
    Abrahamsson, Jonas
    Lund, Bendik
    Jonsson, Olafur G.
    Heilmann, Carsten
    Heyman, Mats
    Schmiegelow, Kjeld
    Vettenranta, Kim
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2019, 184 (06) : 982 - 993
  • [32] Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation
    Lankester, A. C.
    Bierings, M. B.
    van Wering, E. R.
    Wijkhuijs, A. J. M.
    de Weger, R. A.
    Wijnen, J. T.
    Vossen, J. M.
    Versluys, B.
    Egeler, R. M.
    van Tol, M. J. D.
    Putter, H.
    Revesz, T.
    van Dongen, J. J. M.
    van der Velden, V. H. J.
    Schilham, M. W.
    [J]. LEUKEMIA, 2010, 24 (08) : 1462 - 1469
  • [33] Allogeneic Peripheral Blood Stem Cell Transplantation Significantly Increases Risk of Chronic Graft-versus-Host Disease of Lung Compared with Bone Marrow Transplantation
    Alam, Naheed
    Marras, Theodore K.
    Atenafu, Eshetu G.
    Gupta, Vikas
    Kuruvilla, John
    Lipton, Jeffrey H.
    Messner, Hans A.
    Kim, Dennis
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (12) : 1905 - 1910
  • [34] High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma
    Paiva, Bruno
    Gutierrez, Norma C.
    Rosinol, Laura
    Vidriales, Maria-Belen
    Montalban, Maria-Angeles
    Martinez-Lopez, Joaquin
    Mateos, Maria-Victoria
    Cibeira, Maria-Teresa
    Cordon, Lourdes
    Oriol, Albert
    Terol, Maria-Jose
    Echeveste, Maria-Asuncion
    de Paz, Raquel
    de Arriba, Felipe
    Palomera, Luis
    de la Rubia, Javier
    Diaz-Mediavilla, Joaquin
    Sureda, Anna
    Gorosquieta, Ana
    Alegre, Adrian
    Martin, Alejandro
    Hernandez, Miguel T.
    Lahuerta, Juan-Jose
    Blade, Joan
    San Migue, Jesus F.
    [J]. BLOOD, 2012, 119 (03) : 687 - 691
  • [35] Intensified conditioning regimens with total marrow irradiation/etoposide/cyclophosphamide and busulfan/etoposide/cyclophosphamide overcome the impact of pre-transplant minimal residual disease on outcomes in high-risk acute lymphoblastic leukemia patients in complete remission
    Zhao, Xiaoyan
    Xu, Ziwei
    Li, Ziying
    Zhou, Xi
    Hu, Yu
    Wang, Huafang
    [J]. CANCER MEDICINE, 2024, 13 (01):
  • [36] Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Children's Oncology Group ANBL0532 Study
    Liu, Kevin X.
    Naranjo, Arlene
    Zhang, Fan F.
    DuBois, Steven G.
    Braunstein, Steve E.
    Voss, Stephan D.
    Khanna, Geetika
    London, Wendy B.
    Doski, John J.
    Geiger, James D.
    Kreissman, Susan G.
    Grupp, Stephan A.
    Diller, Lisa R.
    Park, Julie R.
    Haas-Kogan, Daphne A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (24) : 2741 - +
  • [37] Residual Disease Burden After Neoadjuvant Therapy Among US Patients With High-Risk HER2-positive Early-Stage Breast Cancer: A Population Effectiveness Model
    Hendrix, Nathaniel
    Oestreicher, Nina
    Lalla, Deepa
    Dolan, Chantal M.
    Fisher, Kathryn A.
    Veenstra, David L.
    Moy, Beverly
    [J]. CLINICAL BREAST CANCER, 2022, 22 (08) : 781 - 791
  • [38] Efficacy of minimal residual disease driven immune-intervention after allogeneic hematopoietic stem cell transplantation for high-risk chronic lymphocytic leukemia: results of a prospective multicenter trial
    Tournilhac, Olivier
    Le Garff-Tavernier, Magali
    Quoc, Stephanie Nguyen
    Forcade, Edouard
    Chevallier, Patrice
    Legrand-Izadifar, Faezeh
    Damaj, Gandhi Laurent
    Michonneau, David
    Tomowiak, Cecile
    Borel, Cecile
    Orvain, Corentin
    Turlure, Pascal
    Redjou, Rabah
    Guillerm, Gaelle
    Vincent, Laure
    Simand, Celestine
    Lemal, Richard
    Quiney, Claire
    Combes, Patricia
    Pereira, Bruno
    Calvet, Laure
    Cabrespine, Aurelie
    Bay, Jacques-Olivier
    Leblond, Veronique
    Dhedin, Nathalie
    [J]. HAEMATOLOGICA, 2021, 106 (07) : 1867 - 1875
  • [39] Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis
    Li, Hanqing
    Li, Feng
    Zhou, Xiaogang
    Mei, Jiangang
    Song, Ping
    An, Zhiming
    Zhao, Qian
    Guo, Xing
    Wang, Xuli
    Zhai, Yongping
    [J]. ANNALS OF HEMATOLOGY, 2019, 98 (05) : 1185 - 1195
  • [40] Relationship between the expression of CD25 and CD69 on the surface of lymphocytes T and B from peripheral blood and bone marrow of patients with chronic lymphocytic leukemia and established prognostic factors of this disease
    Grywalska, Ewelina
    Bartkowiak-Emeryk, Malgorzata
    Pasiarski, Marcin
    Olszewska-Bozek, Karolina
    Mielnik, Michal
    Podgajna, Martyna
    Pieczykolan, Monika
    Hymos, Anna
    Fitas, Elthieta
    Surdacka, Agata
    Gozdz, Stanislaw
    Rolinski, Jacek
    [J]. ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 27 (07): : 987 - 999